Vanda Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 23 trials

TrialDrugs studiedStatusPrimary completion
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisNCT07362017PonesimodRecruiting2028-08Estimated
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044MilsaperidoneRecruiting2028-03Estimated
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaNCT06953869Tasimelteon Oral SuspensionRecruiting2027-11Estimated
Randomized Withdrawal Study in Patients With SchizophreniaNCT06961968iloperidoneRecruiting2027-11Estimated
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNCT07446439TradipitantRecruiting2026-12-01Estimated
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantNCT06701396TasimelteonRecruiting2025-06-30Estimated
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT06138613TradipitantActive not recruiting2027-09-30Estimated
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderNCT07221578VQW-765Active not recruiting2026-12Estimated
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)NCT04652882TasimelteonCompleted2026-09-04Actual
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisNCT06836557TradipitantCompleted2026-03-30Actual
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisNCT04028492Open Label Tradipitant, TradipitantCompleted2025-02-21Actual
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT05903924TradipitantCompleted2024-04-06Actual
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05352893300 mg Imsidolimab, 750 mg ImsidolimabCompleted2023-08-17Actual
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT04327661TradipitantCompleted2023-04-01Actual
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderNCT04819776IloperidoneCompleted2022-09-07Actual
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)NCT03568331TradipitantCompleted2019-12-27Actual
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaNCT03373201TasimelteonCompleted2018-03-05Actual
Relapse Prevention Study in Patients With SchizophreniaNCT01291511IloperidoneCompleted2014-03Actual
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaNCT00254202Iloperidone, ZiprasidoneCompleted2006-09-26Actual
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05366855Double-blind 200 mg imsidolimab, Imsidolimab 750 mg IV/200 mg SC, Open-label 200 mg imsidolimab, Standard of Care (SOC)Terminated2024-07-12Actual
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)NCT04140695TradipitantTerminated2020-10-14Actual
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesNCT05361707Tasimelteon Oral Capsule, Tasimelteon Liquid SuspensionUnknown2025-07Estimated
Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionNCT01218789tasimelteonUnknown2024-12-05Estimated

Phase 2 17 trials

TrialDrugs studiedStatusPrimary completion
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionNCT07090161iloperidoneRecruiting2026-10Estimated
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeNCT07179055VSJ-110Recruiting2026-09Estimated
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisNCT07065773Trichostatin AActive not recruiting2026-09Estimated
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseNCT06804603TradipitantCompleted2025-10-06Actual
Evaluating the Effects of VQW-765 vs. Placebo in Performance AnxietyNCT04800237VQW-765Completed2022-08-02Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaNCT04856930ImsidolimabCompleted2022-07-15Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisNCT04856917ImsidolimabCompleted2022-02-01Actual
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesNCT04622345VSJ-110Completed2021-05-22Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar PustulosisNCT03633396ImsidolimabCompleted2021-04-23Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular PsoriasisNCT03619902ImsidolimabCompleted2021-01-20Actual
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT03772340TradipitantCompleted2019-06-06Actual
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisNCT02970968VLY-686 (Tradipitant)Completed2018-11Actual
Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisNCT02651714TradipitantCompleted2017-08-04Actual
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic DermatitisNCT02004041VLY-686Completed2015-02-19Actual
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform RashNCT04697069ImsidolimabTerminated2021-12-13Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With IchthyosisNCT04697056ImsidolimabTerminated2021-11-19Actual
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeNCT06296966VSJ-110Unknown2024-07Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 100 participants (planned). After: 17 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2025. After: 30 Mar 2026.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 70 participants (planned). After: 43 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2026. After: 4 Sep 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in daily average nausea severity scores from the Gastroparesis Core Symptom Daily Diary (GCS-DD). After: Measure: Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear). After: Measure: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events. After: Measure: Incidence of Adverse Events.

Primary completion date changed

Before: 8 Feb 2024. After: 12 Jul 2024.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear). After: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).

Check registry source